financetom
Business
financetom
/
Business
/
Rhythm Pharmaceuticals EMANATE Trial Fails to Meet Endpoints, Shares Tumble
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rhythm Pharmaceuticals EMANATE Trial Fails to Meet Endpoints, Shares Tumble
Mar 16, 2026 2:25 PM

04:40 PM EDT, 03/16/2026 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Monday that four sub-studies from its EMANATE trial did not meet primary endpoints, sending shares down nearly 6% in recent after-hours trading.

The trial, which tested the drug setmelanotide in patients with rare, genetically driven obesity of the MC4R pathway, showed no new safety signals.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved